Literature DB >> 12595520

Complement inhibitors and glomerulonephritis: are we there yet?

William G Couser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12595520     DOI： 10.1097/01.asn.0000057502.76239.7d

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  4 in total

1.  Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.

Authors:  Roxanne Cofiell; Anjli Kukreja; Krystin Bedard; Yan Yan; Angela P Mickle; Masayo Ogawa; Camille L Bedrosian; Susan J Faas
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 2.  Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications.

Authors:  José M López-Novoa; Ana B Rodríguez-Peña; Alberto Ortiz; Carlos Martínez-Salgado; Francisco J López Hernández
Journal:  J Transl Med       Date:  2011-01-20       Impact factor: 5.531

Review 3.  Therapeutic regulation of complement in patients with renal disease - where is the promise?

Authors:  Johua M Thurman
Journal:  Clin Nephrol       Date:  2012-05       Impact factor: 0.975

4.  Searching for Potential Markers of Glomerulopathy in Urine by HS-SPME-GC×GC TOFMS.

Authors:  Tomasz Ligor; Joanna Zawadzka; Grzegorz Strączyński; Rosa M González Paredes; Anna Wenda-Piesik; Ileana Andreea Ratiu; Marek Muszytowski
Journal:  Molecules       Date:  2021-03-24       Impact factor: 4.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.